Payload Information
General Information of This Payload
| Payload ID | PAY0VGQXF |
|||||
|---|---|---|---|---|---|---|
| Name | CL202203715A1 P5 |
|||||
| Synonyms |
CL202203715A1 P5
Click to Show/Hide
|
|||||
| Structure |
|
|||||
| Formula | C53H80FN9O9S |
|||||
| Isosmiles | CCCCCCN(C([C@@H](NC([C@H]1CCCCN1C)=O)[C@H](CC)C)=O)[C@@H](C(C)C)C[C@@H](OC(NCCNC(OCC(C=C2)=CC=C2N)=O)=O)C3=NC(C(N[C@@H](CC4=CC=C(N)C(F)=C4)CC(C)(C)C(O)=O)=O)=CS3 |
|||||
| InChI |
InChI=1S/C53H80FN9O9S/c1-9-11-12-14-26-63(49(66)45(34(5)10-2)61-47(65)42-16-13-15-25-62(42)8)43(33(3)4)29-44(72-52(70)58-24-23-57-51(69)71-31-35-17-20-37(55)21-18-35)48-60-41(32-73-48)46(64)59-38(30-53(6,7)50(67)68)27-36-19-22-40(56)39(54)28-36/h17-22,28,32-34,38,42-45H,9-16,23-27,29-31,55-56H2,1-8H3,(H,57,69)(H,58,70)(H,59,64)(H,61,65)(H,67,68)/t34-,38-,42+,43+,44+,45-/m0/s1
|
|||||
| InChIKey |
XXAXMBLXCQHZFJ-BCXOSXMNSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
1038.342 |
Polar area |
260.64 |
||
Complexity |
2188.696242 |
xlogp Value |
7.8211 |
|||
Heavy Count |
73 |
Rot Bonds |
28 |
|||
Hbond acc |
13 |
Hbond Donor |
7 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
TRSQ-ZP3A-LP18 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.118 nM
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 23% FBS,penicillin/streptomycin and L-glutamine.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
TRSQ-ZP3A-LP19 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.135 nM
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 24% FBS,penicillin/streptomycin and L-glutamine.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
TRSQ-ZP3A-LP16 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.182 nM
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 22% FBS,penicillin/streptomycin and L-glutamine.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||